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Although disseminated blastomycosis is a rare complication in pregnancy, delay in diagnosis and treatment can be fatal. We in-
vestigate the use of the Blastomyces urine antigen in diagnosis following disease progression in the intrapartum, postpartum, and
neonatal periods. We describe a case of disseminated blastomycosis in a pregnant adolescent and review the pertinent literature
regarding treatment and monitoring blastomycosis in pregnancy and the neonatal periods. This is the ﬁrst reported case in which
the Blastomyces urine antigen is utilized as a method of following disease activity during pregnancy conﬁrming absence of clini-
cally evident disease in a neonate. Urine antigen detection for blastomycosis can be useful for following progression of disease in
patients with disseminated blastomycosis in both the intrapartum and postpartum periods.
Copyright © 2007 Megan Tarr et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Blastomyces dermatitidis is a dimorphic fungus endemic to
the Ohio River and Mississippi River valleys and the Great
Lakes Region. The fungus is found in soil, bird manure, and
decaying vegetation. Inoculation is achieved through inhala-
tion of the spores. Patients often report fatigue, a productive
cough, weight loss, fever, and are hospitalized for presump-
tive bacterial pneumonia. The median number of days from
exposure to onset of blastomycosis infection is 45 days [1].
Besidespneumonia,otherclinicalmanifestationsincludecu-
taneous papular lesions, osteomyelitis, and frank fungemia;
theselattermanifestationsaresecondarytodisseminateddis-
ease. Infection with Blastomyces dermatitidis can have a mor-
tality rate ranging from 4.3% to 22% with higher mortality
rates among those infected with HIV [1]. In pregnancy, cell-
mediated immunity is impaired. This state of immunosup-
pression can facilitate the reactivation of the disease or the
initial disease presentation [2].
Although spontaneous resolution of the disease can oc-
cur, the most common antifungal agent used in treatment
of individuals is amphotericin B deoxycholate [1, 3]. Am-
photericin B is also the drug of choice in pregnant women
and has also been used to treat disseminated blastomycosis
in pregnancy with no increased risks of adverse medication
eﬀects on the mother and no reports of teratogenicity in ex-
posures in all three trimesters [3, 4].
2. CASE
A previously healthy 14-year-old African-American female
wasreferredtotheOrthopedicSurgeryClinicatUniversityof
Chicago Comer Children’s Hospital (UCCH) by her primary
physicianforanevaluationofpersistentlowbackpain.Atthe
time of this visit in October 2003, she had a 4-week history
of intermittent fever to 40◦C, multiple skin lesions, fatigue,
right 4th digit swelling, and a weight loss of 30 pounds. She
was admitted to the intensive care unit for management of
respiratory distress. On physical examination, she appeared
to be short of breath and required oxygen due to low arterial
o x y g e ns a t u r a t i o no nr o o ma i r( 8 8 % ) .S h eh a da2c mu l c e r -
ative draining skin wound on the back of the left shoulder as
well as 1 × 1cm nodules over her arms, legs, and trunk. Her
spleen was palpable 2cm below the left costal margin. Her
lungs were clear to auscultation.
Initial laboratory studies upon admission were signiﬁ-
cant for an elevation of aminotransferase enzymes (AST of
316U/LandALTof332U/L),erythrocytesedimentationrate2 Infectious Diseases in Obstetrics and Gynecology
(129mm/h), and c-reactive protein (140mg/L). A chest ra-
diograph showed a diﬀuse reticulonodular inﬁltrative pat-
tern. Magnetic resonance imaging (MRI) of the thoracic and
lumbarspineshowedaparavertebralabscessatL5-S1andos-
teomyelitis involving the T12, S1-S2 vertebral bodies and the
right iliac bone.
A biopsy of a cutaneous nodule revealed broad-based
budding yeasts on fungal smear that were morphologically
consistent with Blastomyces dermatitidis. Sputum and skin
biopsy cultures grew Blastomyces dermatitidis. Blastomyces
antigen detection in urine was highly elevated at 37.69 EIA
units (normal range <1 EIA units). Serologic assays (both
complement ﬁxation and immunodiﬀusion) for blastomy-
cosis were negative. She was started on amphotericin B at
1mg/kg/dayfor2weeksandswitchedtotheoralitraconazole
suspension 100mg twice a day. The liver function tests im-
proved gradually and were approaching normal before dis-
charge. Prior to discharge, her back pain had resolved, and
her respiratory status had normalized. An HIV antibody test
was negative.
InJuly2004,shewasreadmittedtoUCCHduetomassive
swelling of her right 4th digit. At that time, Blastomyces anti-
gen detection in urine remained elevated at 28.77 EIA units.
These ﬁndings raised the concern of nonadherence to itra-
conazole, which was supported by multiple failed clinic ap-
pointments. A plain radiograph of right hand showed ﬁnd-
ings consistent with osteomyelitis. After a consultation with
the orthopedic surgery service, amputation of the right 4th
ﬁnger was considered. Instead, intravenous amphotericin B
at1mg/kg/daywasinitiated.Ariseinserumcreatinine(from
0.5mg/dL to 2.5mg/dL) occurred, and the antifungal reg-
imen was changed to amphotericin B lipid complex. She
demonstrated a remarkable decrease in swelling of the right
4thﬁngerafterbeginningthisregimen.AmphotericinBlipid
complex was continued for 6 weeks followed by oral itra-
conazole capsules 100mg twice per day. Surgery on the right
fourth ﬁnger was unnecessary, and further MRIs of the spine
showed resolution of the paravertebral abscess and decrease
in signal intensity of the right sacral and iliac bones. Com-
plement levels, lymphocyte subset levels, and IgA, IgM levels
were normal. IgG levels were slightly elevated at 1722mg/dL.
She again was seen intermittently after the second hospital-
ization. When she returned to the pediatric infectious dis-
eases clinic for followup in May 2005 (18 months after the
initial diagnosis), she disclosed that she was 20-week preg-
nant. At this visit, the Blastomyces urine antigen remained
elevated at 24.80 EIA units (Figure 1). Due to limited data
concerning the use of itraconazole during pregnancy, which
isclassiﬁedasacategoryCmedication,shewascounseledre-
gardingthepossiblerisktothedevelopingfetus.Itraconazole
was discontinued, and treatment with intravenous liposomal
amphotericin B was recommended by the pediatric infec-
tious disease service. Although further antifungal treatment
was refused, she was closely followed in the pediatric in-
fectious disease clinic with physical examinations and serial
monitoring of the urine Blastomyces antigen test. The Blasto-
myces urine antigen remained stable but elevated throughout
the third trimester of pregnancy (17.52–26.44 EIA units) up
Mother
Baby
1
10
100
E
U
1
0
/
1
/
0
4
1
/
1
/
0
5
4
/
1
/
0
5
7
/
1
/
0
5
1
0
/
1
/
0
5
1
/
1
/
0
6
4
/
1
/
0
6
7
/
1
/
0
6
1
0
/
1
/
0
6
1
/
1
/
0
7
Figure 1: Blastomyces antigenuria during and after pregnancy for
mother-baby pair.
to 36-week gestation (Figure 1). The patient had one limited
structural survey ultrasound performed at 17 weeks; results
wereunremarkable.Duetothepatient’s insurancestatus,the
patient was not referred to the Maternal Fetal Medicine De-
partment at the University of Chicago until 34-week gesta-
tion; she, however, delivered prior to her ﬁrst visit. She had
not received any antenatal testing.
Thepatientpresentedtothelaboranddeliveryunitinac-
tive labor at term with intact amnionic membranes and im-
mediatelyreceivedone400mg(5mg/kg)doseoftheampho-
tericin B lipid complex. The patient also developed a fever 6
hours prior to delivery and was treated for chorioamnionitis
in labor.
The patient delivered a healthy female infant weighing
2600g with APGARS of 9 at one and ﬁve minutes. The pa-
tientwasrestartedonoralitraconazolecapsules200mgtwice
daily in the postpartum period. The mother had no further
fever while hospitalized and was discharged on postpartum
day number three. She received depomedroxyprogesterone
acetate for contraception prior to discharge.
The placenta had no granulomas, and fungal culture
from the placenta was negative. The infant’s blood cultures
at birth showed no growth, and urine and serum sent for
Blastomyces antigen testing were also negative. A chest radio-
graph of the infant was also normal. At 2 and 3 weeks of life,
the infant had a weakly positive urine Blastomyces antigen
test, but subsequent urine samples sent up to age 12 weeks
were negative (Figure 1).
Postpartum management included continuation of itra-
conazole capsules, 200mg twice per day, biweekly mon-
itoring of urine Blastomyces antigen levels, and monthly
visits to the Pediatric Infectious Disease Clinic. Blasto-
myces urine antigen was persistently elevated for 5 months
following delivery, and a measured serum itraconazole
level was <0.3µg/mL (expected value- 0.3–7.0µg/mL). TheMegan Tarr et al. 3
itraconazole was changed from the capsule to the suspension
form because of concern regarding absorption of the capsule
formulation. Two weeks after the change in itraconazole for-
mulation, a repeat itraconazole level drawn 1.5 hours after a
direct observed dose was 2.4µg/mL. She was clinically well
in follow-up while receiving antifungal therapy, and a Blasto-
myces urine antigen level measured 13 months after delivery
has decreased to 6.22 EIA units (Figure 1).
3. COMMENT
Blastomycosis is an endemic mycosis in Southeastern, South
central, and Midwestern states and is particularly prevalent
in areas adjacent to the Mississippi and Ohio Rivers and the
Great Lakes region. A recent Illinois Public Health Depart-
ment epidemiological study of 500 cases of blastomycosis
in Illinois reported no cases of blastomycosis in pregnant
women over a ten-year period [1]. Although Mississippi is
designated as the area with the highest prevalence of blasto-
mycosis in the United States, studies from this region rarely
report its incidence in pregnancy [2]. The clinical manifesta-
tions of blastomycosis during pregnancy are highly variable
ranging from self-limited illness without treatment in some
case reports [2] to disseminated infection [4], or acute respi-
ratory distress syndrome [5].
Although fungal culture still remains the deﬁnitive diag-
nostic test, growth may be slow, which limits its value for
early diagnosis. In contrast, antigen testing has the potential
for rapid diagnosis of blastomycosis. The urine antigen test
forblastomycosishashighsensitivity(92%)forthedetection
of the blastomycosis and excellent speciﬁcity (>98%) in pa-
tients without fungal infections, but is highly cross-reactive
in those with histoplasmosis, paracoccidioidomycosis, and
Penicilliosis marneﬀei [6]. Urine antigen detection of blasto-
mycosis has recently been shown to be useful for followup
duringtherapyofblastomycosisinpediatricpatients,includ-
ing the present adolescent patient prior to the pregnancy [7].
The eﬀect of pregnancy on urine antigen for diagnosis of
blastomycosis is not known, but our case illustrates that lev-
els of antigen in the urine will persist if antifungal therapy
is stopped or not taken consistently. Based on the experi-
ence with the urine antigen test for histoplasmosis [8], the
urine antigen levels found in our adolescent are consistent
with presumptive evidence of continued infection with blas-
tomycosis.
Itisofinterestthatourpatient’slevelofurineBlastomyces
antigen remained elevated in the 16–26 EIA unit range both
during cessation of treatment during pregnancy and after
reinitiation of treatment after delivery. The initial decrease
in Blastomyces urine antigen levels occurred in the weeks fol-
lowing the short course of intravenous amphotericin B given
during labor and while itraconazole was administered in the
postpartum period. The decrease in urine antigen levels oc-
curring a year after delivery indicates a successful response to
antifungal therapy. The ﬁnal outcome, however, remains to
be determined. Our patient continues to receive antifungal
therapy, and low-level antigenuria persists.
Blastomycosis can be transmitted from an infected preg-
nant woman to the newborn infant. The route of acquisition
is not well established, and there are few reported cases. In a
review of perinatal blastomycosis, transmission to the new-
born infant was proposed to be through aspiration of colo-
nizedvaginalsecretionsassuggestedbyprimarilypulmonary
involvement in aﬀected newborns and through hematoge-
nous spread as evidenced by placental involvement [2, 9, 10].
There are no previous reports examining the use of Blasto-
myces urine antigen for diagnosis of newborn infants born to
mothers with blastomycosis during pregnancy. In the past,
diagnosis in the newborn has been through fungal culture,
pulmonary cytology, or wet prep [2]. In our case, the infant
did not develop any clinical manifestations of disease. This
correlated with the transient, low Blastomyces urine antigen
levels in the neonatal period that cleared with additional
followup. Our case also illustrates that urine antigen detec-
tion for blastomycosis can be useful for following progres-
sion of disease in patient with disseminated blastomycosis
in both the intrapartum and postpartum periods. Additional
research is needed to determine the utility of the Blastomyces
urineantigentestfordiagnosisandmonitoringdisseminated
blastomycosis.
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